{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-a/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field 91dc880c-6154-4435-a7e7-8d9cbec78266 --><h2>What investigations should I do?</h2><!-- end field 91dc880c-6154-4435-a7e7-8d9cbec78266 -->","summary":"","htmlStringContent":"<!-- begin item e1c6850b-44d9-412a-b7fd-a6c19e602626 --><!-- begin field 2bc7a265-96d6-42a3-8ef5-2ab6318c7e58 --><p><strong>The following tests should be carried out if hepatitis A is suspected:</strong></p><ul><li><strong>Hepatitis serology</strong> — note: suspicion of hepatitis A should be specifically stated on the request form. <ul><li><strong>Be aware that:</strong><ul><li>The most sensitive test for diagnosing acute hepatitis A infection is a PCR test for hepatitis A RNA, however, this test is not widely available. </li><li>In the absence of routine RNA testing, detection of hepatitis A virus immunoglobulin M (HAV-IgM) and hepatitis A virus immunoglobulin G (HAV-IgG)<strong> </strong>should both ideally be conducted to strengthen diagnostic accuracy.</li><li>HAV-IgM antibodies are detectable from at least five days after the onset of symptoms, peak during the acute or early convalescent phase of the disease, and usually remain positive for  45—60 days but can persist for around six months.</li><li>HAV-IgG antibodies are detectable 5–10 days after the onset of symptoms and then persist.</li><li>Many laboratories use a hepatitis A total antibody assay instead of a pure IgG assay to check immune status.</li></ul></li><li><strong>If serology shows:</strong><ul><li><strong>Positive HAV-IgM, and positive HAV-IgG — </strong>acute hepatitis A infection is likely.</li><li><strong>A high IgG reactivity and a moderate level of IgM </strong>— suggests hepatitis A infection in the recent past rather than current acute infection.</li><li><strong>Positive HAV-IgM, and negative HAV-IgG — </strong>IgM result may be a false positive.</li><li><strong>Negative HAV-IgM, and positive HAV-IgG — </strong>suggests past hepatitis A infection, or immunity from previous vaccination.</li></ul></li><li><strong>Serology results should be interpreted in the broader context of:</strong><ul><li>Timing of illness onset —if serology is taken in the first 7–10 days of <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/diagnosis/clinical-features/\">symptoms</a>, there is a small risk of a false negative result, so serology should be repeated 1–2 weeks later.</li><li>The age of the person (false IgM results are more likely in older people, a group likely to have had hepatitis A in childhood).</li><li>Co-morbidities — HAV IgM serology may not be reliable in patients who are significantly immunocompromised.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-a/background-information/risk-factors/\">Risk factors</a> for hepatitis A.</li><li>Results of liver function tests (see below)</li></ul></li></ul></li><li><strong>Liver function tests</strong>.<ul><li>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels may be significantly increased (usually between 500 and 10,000 IU/L).</li><li>Bilirubin may be elevated (usually between 85.5 and 171 micromols/L but can reach up to 500 micromols/L).</li><li>Alkaline phosphatase is generally < 2x the upper limit of normal, but higher if there is cholestasis.</li><li>Prothrombin time may be prolonged ( 5 seconds or more suggests severe hepatitis and 50 seconds or more suggests acute liver failure).</li></ul></li></ul><!-- end field 2bc7a265-96d6-42a3-8ef5-2ab6318c7e58 --><!-- end item e1c6850b-44d9-412a-b7fd-a6c19e602626 -->","topic":{"id":"29ac65ab-afdd-58a1-bb07-9c101977d24d","topicId":"580cfa7a-647b-439a-8f8c-493cb6bd4332","topicName":"Hepatitis A","slug":"hepatitis-a","lastRevised":"Last revised in January 2021","chapters":[{"id":"d47cd8cf-fe05-5aa4-997b-01a20519d12f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bbe6550-f4f5-5279-9e9e-04b38f9dc672","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75791cbd-6d69-555e-83e8-9ac8cca25c50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c0ae1a2d-febe-5ec7-821a-0616062456ee","slug":"changes","fullItemName":"Changes"},{"id":"434eb73d-f60d-5f1f-ba10-5aa77d904da1","slug":"update","fullItemName":"Update"}]},{"id":"242c9e8c-5867-5598-9168-62160e8ae293","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6c2f4656-f9e8-56be-aa43-3f6a9aa45aa8","slug":"goals","fullItemName":"Goals"},{"id":"71c0a726-22c7-568b-b925-d10cc97ace3a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"70e8a1cd-fd5b-50d7-8ce4-b6f29981218d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"37bb7a58-62c9-52be-b97c-7b99f8317f12","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"badbd40f-9ce6-5f8a-9f65-8be03bc8d3fe","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed9f7297-1f33-5365-8e4f-3844542af45d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a11034-e31c-5039-8ca7-b463c00b2039","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a2206363-5f44-5348-b469-07b49a6a9647","slug":"definition","fullItemName":"Definition"},{"id":"dd1ca873-1bf9-500d-a574-fc92c8589e62","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bdd89354-2f0b-564c-b589-cb043e32b99c","slug":"transmission","fullItemName":"Transmission"},{"id":"8e72bb81-12fd-5a0e-976b-d18d62788974","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ab3f5823-00db-5e27-a434-c323c357ab02","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"94f8b729-5e94-57ee-b96e-ca1561614640","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6b32fed7-c15e-5976-adc6-692994cbab9e","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"2503640c-54cf-53e1-b29c-fc9c19cbd52a","slug":"investigations","fullItemName":"Investigations"},{"id":"88a35298-3760-53b6-b4ff-b9e0677b4df3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9ba7b244-14ec-5fd1-9b2b-151b9c48bfab","fullItemName":"Management","slug":"management","subChapters":[{"id":"1a3874e3-8562-5ca6-8c97-4d9a2a009e75","slug":"prevention-of-infection-with-hepatitis-a","fullItemName":"Scenario: Prevention of infection with hepatitis A"},{"id":"49c1d671-61dd-5a60-974f-069b03d80d11","slug":"managing-hepatitis-a-infection","fullItemName":"Scenario: Managing hepatitis A infection"},{"id":"449ffa79-3397-54a1-a4d5-0efa55ee889f","slug":"contact-with-hepatitis-a","fullItemName":"Scenario: Contact with hepatitis A"}]},{"id":"8ffd203a-96db-5a38-a7bd-0186b97b6600","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"7d022e5d-ab4e-50bf-b90f-5611cf3a17db","slug":"hepatitis-a-vaccine","fullItemName":"Hepatitis A vaccine"},{"id":"7d0e86fd-3666-5a09-b539-4497227285ee","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0ee2b156-78a9-52f6-ab80-fff22c46ff66","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"508e578c-aa68-5cdb-aa90-ef8889919c08","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"bf6b787f-fbb7-5d8d-bd85-cfe063c76fcd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e0bba353-de5a-55b9-9171-a677ecc4b97a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2571e87f-4ad0-5f6d-8c0e-8c9c86054278","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"94bd9363-8cd1-5ba6-8fd3-11f5a3ce29dd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2db0f1a2-7d4b-5fd2-a8bf-db32553e5b89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"29233885-dedb-5c3b-ba7e-1aae299ecfe2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0a3a365f-c89a-5f1e-8ce5-1078ade19779","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1afe9613-76a4-50b9-8941-c2a2ebec23cc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e879b74c-3d75-59c5-806e-4b39a6e72901","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"61028ac6-c419-5350-822c-35a5af86fe8e","slug":"basis-for-recommendation-48d","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field b29f83f9-ef6a-456e-83a2-9d0aaa40cb15 --><h3>Basis for recommendation</h3><!-- end field b29f83f9-ef6a-456e-83a2-9d0aaa40cb15 -->","summary":null,"htmlStringContent":"<!-- begin item 48d54a0b-10e2-4cf4-9f5e-72ad94fc11fa --><!-- begin field 619e0e8d-3620-49a5-a826-7d7df4c6c872 --><p> The recommendations on investigations to confirm a diagnosis of hepatitis A are largely based on expert opinion in the British Association of Sexual Health and HIV (BASHH) <em>National Guidelines for the Management of the Viral Hepatitides</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>], the Public Health England guidelines <em>Public health control and management of hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2017</a>], and <em>UK Standards for Microbiology Investigations: Hepatitis A virus acute infection serology</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">PHE, 2019b</a>] and the BMJ Best Practice guideline <em>Hepatitis A</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BMJ Best Practice, 2018</a>].</p><h4>Hepatitis serology requests</h4><ul><li>The recommendation to state any suspicion of hepatitis A on the laboratory request form when ordering hepatitis serology is based on the opinion of a previous expert reviewer of this CKS topic. Hepatitis A may not be routinely included in hepatitis serology screens in all laboratories in the UK, so it should be specifically requested if required. Additionally, as the clinical features of acute hepatitis A cannot readily be distinguished from other forms of acute hepatitis, and some people may have co-infection with hepatitis B or C, a full hepatitis screen may be advised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">British Liver Trust, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">BASHH, 2017</a>].</li></ul><h4>Repeat serology</h4><ul><li>The recommendation to repeat HAV-IgM levels 1–2 weeks later, if the person has had an initial negative result but is in the first 7–10 days of symptoms (to exclude a false-negative result), is based on expert opinion in a hepatitis A review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-a/references/\">Cuthbert, 2001</a>] and the opinion of a previous expert reviewer of this CKS topic.</li></ul><!-- end field 619e0e8d-3620-49a5-a826-7d7df4c6c872 --><!-- end item 48d54a0b-10e2-4cf4-9f5e-72ad94fc11fa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}